ANTIVIRAL DRUGS ADVISORY COMMITTEE
(Discuss the Use of Surrogate Markers in the Early Development of
Immunomodulatory Agents for the Treatment of Patients with Human
Immunodeficiency Virus (HIV))
October 16, 2000
Slides
Need for New Therapies, Lawrence Fox, MD, PhD ppt html
An Overview of Candidate Immunologic Biomarkers and Surrogate Markers, Alan Landay, PhD ppt html
Surrogate Markers as Measures of Efficacy: Limitations & Complexities, Thomas R Fleming PhD pdf
CDER Meeting: Surrogate Markers of Immunity, Judith A Britz, PhD ppt html
The Role of Glutathione in Cell Defense, with References to Clinical Deficiencies and Treatment, Thomas A Kwyer, MD ppt html